SCHEMBL15907985

SCHEMBL15907985

Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2OC(=O)CCC(=O)ON1C(=O)CCC1=O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 11/20 0.69
HTR2A P28223 10/20 0.69
HTR2C P28335 4/20 0.69
HRH1 P35367 4/20 0.69
DRD3 P35462 4/20 0.69
KCNH2 Q12809 4/20 0.69
ADRA1A P35348 3/20 0.69
DRD1 P21728 3/20 0.69
ADRA2A P08913 2/20 0.69
ADRA2B P18089 2/20 0.69
ADRA2C P18825 2/20 0.69
DRD4 P21917 2/20 0.69
DRD5 P21918 2/20 0.69
HTR1D P28221 2/20 0.69
HTR1B P28222 2/20 0.69
HTR7 P34969 2/20 0.69
SCN5A Q14524 2/20 0.69
KCND3 Q9UK17 1/20 0.69
ACHE P22303 3/20 0.63
HTR1A P08908 3/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6881431 0.97 DRD2 (0.67) DRD2HTR2AHTR2CHRH1DRD3
SCHEMBL1958487 0.92 HTR2A (0.73) DRD2HTR2AHTR2CHRH1DRD3
SCHEMBL15907987 0.91 DRD2 (0.65) DRD2HTR2AHTR2CHRH1DRD3
SCHEMBL21074540 0.90 DRD2 (0.64) DRD2HTR2AHTR2CHRH1DRD3
SCHEMBL19484373 0.90 HTR2A (0.76) DRD2HTR2AHTR2CHRH1DRD3
SCHEMBL15489555 0.89 DRD2 (0.68) DRD2HTR2AHTR2CHRH1DRD3
SCHEMBL1961482 0.89 DRD2 (0.72) DRD2HTR2AHTR2CHRH1DRD3
SCHEMBL6881873 0.89 DRD2 (0.72) DRD2HTR2AHTR2CHRH1DRD3
SCHEMBL24018542 0.89 DRD2 (0.71) DRD2HTR2AHTR2CHRH1DRD3
SCHEMBL21295308 0.89 DRD2 (0.71) DRD2HTR2AHTR2CHRH1DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3556759-B1 HAPTENS OF PALIPERIDONE JANSSEN PHARMACEUTICA NV (BE) 2023-11-29 EP disclosed
EP-3556759-A1 HAPTENS OF PALIPERIDONE Janssen Pharmaceutica NV (BE) 2019-10-23 EP disclosed
EP-2888258-B1 HAPTENS OF PALIPERIDONE JANSSEN PHARMACEUTICA NV (BE) 2019-06-05 EP disclosed
US-9394354-B2 Haptens of paliperidone JANSSEN PHARMACEUTICA NV (BE) 2016-07-19 US disclosed
US-9394354-B2 Haptens of paliperidone JANSSEN PHARMACEUTICA NV (BE) 2016-07-19 US disclosed
US-20140213767-A1 HAPTENS OF PALIPERIDONE ORTHO-CLINICAL DIAGNOSTICS, INC. (US) 2014-07-31 US disclosed
US-20140213767-A1 HAPTENS OF PALIPERIDONE ORTHO-CLINICAL DIAGNOSTICS, INC. (US) 2014-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140213767-A1 HAPTENS OF PALIPERIDONE CD274, PIN1, LY96 DRD2 430/4885HTR2A 864/4885HTR2C 735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.